NCT07250087RecruitingPhase 1
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Phase 1 Study of Asciminib Maintenance Therapy Following Allogeneic Stem Cell Transplant or Chimeric Antigen Receptor T Cell Therapy (CAR T) to Prevent Relapse in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults: one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 21 Jan 2026
- Primary completion date
- 30 Nov 2029
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Acute lymphoblastic leukaemia
- NCT number
- NCT07250087
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- From 21 Jan 2026 to the primary completion date, 30 Nov 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Grade II-IV acute GVHD requiring systemic steroids
- Prior investigational CAR T product
Other illness
- Active relapsed disease (\>5% blasts)
- Significant organ dysfunction or uncontrolled infection
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Age ≥18 years
- Diagnosis of Ph+ B-ALL with detectable Philadelphia chromosome abnormalities
- Morphologic remission (\<5% marrow blasts)
- ECOG performance status 0-2
- Adequate organ function
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.